tiprankstipranks
Trending News
More News >
Valneva Se (VALN)
:VALN
US Market
Advertisement

Valneva (VALN) Earnings Dates, Call Summary & Reports

Compare
328 Followers

Earnings Data

Report Date
Mar 19, 2026
TBA (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
-0.33
Last Year’s EPS
-0.49
Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 20, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The company showed positive developments in revenue growth and cash management, along with promising clinical advancements. However, challenges remain with IXCHIQ sales suspension, DUKORAL sales decline, and operating losses.
Company Guidance
In the recent conference call, Valneva provided guidance on its financial performance and strategic direction for the remainder of 2025 and beyond. The company reported total revenues of EUR 127 million for the first nine months of 2025, marking an increase of nearly 9% from the previous year, despite geopolitical and product-specific challenges. Product sales reached EUR 119.4 million, with IXIARO sales growing 12.5% to EUR 74.3 million, driven by demand from the U.S. Department of Defense and European markets. However, DUKORAL sales slightly decreased to EUR 21.5 million, impacted by currency fluctuations and a distributor transition in Germany. IXCHIQ sales saw a notable increase to EUR 7.6 million, despite a temporary U.S. license suspension affecting travel segment sales. Valneva's cash reserves stood at EUR 143.5 million as of September 30, 2025, bolstered by EUR 26 million from ATM transactions. The company maintained its full-year guidance, projecting product sales between EUR 155 million and EUR 170 million, and total revenues ranging from EUR 165 million to EUR 180 million. Looking ahead, Valneva emphasized the significant potential of its Lyme disease vaccine, VLA15, which is on track for regulatory submissions in 2026 and anticipated market launch in late 2027, positioning it as a key growth driver for sustained profitability.
Revenue Growth
Total revenues reached EUR 127 million, marking a growth of almost 9% despite geopolitical and IXCHIQ-specific challenges.
Operating Cash Burn Reduction
Significant reduction in operating cash burn, resulting in a cash position of more than EUR 140 million.
Debt Refinancing Success
Successfully completed debt refinancing, enhancing financial flexibility with Pharmakon as a new partner.
IXIARO Sales Increase
IXIARO sales reached EUR 74.3 million, a 12.5% increase driven by sales to the U.S. Department of Defense and increased sales in Europe.
Positive Clinical Data
Reported positive safety and immunogenicity data for the Lyme vaccine candidate and positive Phase I results for the Zika vaccine candidate.

Valneva (VALN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

VALN Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Mar 19, 2026
2025 (Q4)
-0.33 / -
-0.486
Nov 20, 2025
2025 (Q3)
-0.36 / -0.56
-0.11-410.00% (-0.45)
Aug 12, 2025
2025 (Q2)
-0.32 / -0.16
-0.38357.70% (+0.22)
May 07, 2025
2025 (Q1)
-0.34 / -0.14
0.884-115.84% (-1.02)
Mar 20, 2025
2024 (Q4)
-0.21 / -0.49
-0.5094.52% (+0.02)
Nov 07, 2024
2024 (Q3)
-0.27 / -0.11
-0.53779.52% (+0.43)
Aug 13, 2024
2024 (Q2)
-0.34 / -0.38
-0.191-100.52% (-0.19)
May 07, 2024
2024 (Q1)
1.12 / 0.88
-0.286409.09% (+1.17)
Mar 20, 2024
2023 (Q4)
0.09 / -0.51
-0.407-25.06% (-0.10)
Nov 09, 2023
2023 (Q3)
-0.45 / -0.54
1.242-143.24% (-1.78)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

VALN Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 20, 2025
$8.70$8.53-1.95%
Aug 12, 2025
$8.50$9.40+10.59%
May 07, 2025
$6.48$6.59+1.70%
Mar 20, 2025
$6.73$7.25+7.73%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Valneva Se (VALN) report earnings?
Valneva Se (VALN) is schdueled to report earning on Mar 19, 2026, TBA (Confirmed).
    What is Valneva Se (VALN) earnings time?
    Valneva Se (VALN) earnings time is at Mar 19, 2026, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is VALN EPS forecast?
          VALN EPS forecast for the fiscal quarter 2025 (Q4) is -0.33.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis